Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences has finalized an agreement with Lovelace Respiratory Research Institute to provide a broad range of product development services pertaining to inhalation and intranasal drug delivery, and associated regulatory affairs support.
Subscribe to our email newsletter
This strategic relationship is expected to support company’s preparation for an investigational new drug application for Homspera.
Efforts to be pursued at Lovelace will involve both the inhalational administration of Homspera, which was used in early radioprotection studies, as well as the intranasal administration used more recently in the studies demonstrating anti-viral activity, vaccine adjuvant activity, and hematologic stem cell.